Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abiraterone acetate + methylprednisolone
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Abiraterone acetate + methylprednisolone is a combination therapy used primarily for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (CSPC). Abiraterone acetate is a prodrug of abiraterone, which acts as a selective and irreversible inhibitor of the enzyme steroid 17-hydroxylase/17,20 lyase (CYP17A1), thereby blocking androgen biosynthesis that fuels prostate cancer growth. Methylprednisolone, a synthetic glucocorticoid corticosteroid, is co-administered to mitigate mineralocorticoid-related side effects such as hypertension, hypokalemia, and fluid retention caused by CYP17A1 inhibition. The combination improves survival in patients with advanced prostate cancer who have progressed despite androgen deprivation therapy[2][3][5][8].
- Brand names
- Yonsa
- Other names
- abiraterone + methylprednisolone
02
Targets
GR (Glucocorticoid receptor)CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)
Beyond the preview
Go deeper on abiraterone acetate + methylprednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abiraterone acetate + methylprednisolone.